CLVSF: AI 评分 52/100 — AI 分析 (4月 2026)

CellaVision AB (publ) specializes in developing and selling digital solutions for blood and body fluid analysis, primarily serving the healthcare sector. Their products automate and standardize the morphological examination process for hospital and commercial laboratories.

Key Facts: AI Score: 52/100 Sector: Healthcare

公司概况

概要：

CellaVision AB (publ) provides digital solutions for blood and body fluid analysis, automating and standardizing morphological examination. Serving hospitals and commercial labs globally, the company's key differentiators include its advanced cell imaging technology and comprehensive software suite, positioning it as a leader in hematology diagnostics within the medical devices sector.

CLVSF是做什么的？

CellaVision AB (publ), founded in 1994 and headquartered in Lund, Sweden, develops and markets digital solutions for blood and body fluid analysis. The company's core products include the CellaVision DM1200, DM9600, and DC-1 analyzers, which automatically capture digital images of cells from blood smears and body fluid preparations. These analyzers are complemented by a suite of software applications, such as the CellaVision Peripheral Blood Application, Advanced RBC Application, Body Fluid Application, and Remote Review Software, designed to automate, standardize, and simplify morphological examination. CellaVision's solutions cater to hospital and commercial laboratories, enabling them to streamline workflows, improve accuracy, and enhance efficiency in hematology diagnostics. The company's geographic reach extends across Europe, the Middle East, Africa, the Americas, and the Asia Pacific. CellaVision differentiates itself through its integrated hardware and software approach, offering a comprehensive solution for digital cell morphology. This positions them competitively against other players in the medical devices market, particularly those focused on laboratory automation and diagnostics.

CLVSF的投资论点是什么？

CellaVision AB (publ) presents a notable market position within the medical devices sector, driven by the increasing demand for automated and standardized diagnostic solutions. The company's strong gross margin of 68.5% and profit margin of 20.2% indicate efficient operations and pricing power. Growth catalysts include the expansion of its product portfolio and penetration into new geographic markets. Key value drivers include the recurring revenue from software licenses and service contracts, as well as the potential for increased adoption of its solutions in veterinary medicine. Potential risks include competition from established players and the impact of regulatory changes on the medical devices industry. The company's P/E ratio of 23.09 suggests a premium valuation, reflecting investor expectations for future growth.

CLVSF在哪个行业运营？

CellaVision AB (publ) operates within the medical devices industry, specifically focusing on in-vitro diagnostics and laboratory automation. The industry is characterized by technological advancements, increasing regulatory scrutiny, and growing demand for accurate and efficient diagnostic solutions. The global in-vitro diagnostics market is projected to reach $100 billion by 2028, driven by the rising prevalence of chronic diseases and the increasing adoption of point-of-care testing. CellaVision competes with other medical device manufacturers and diagnostic companies, including AVNBF (Avon Rubber P.L.C.) and BJTRF (Bio-Rad Laboratories, Inc.), in a fragmented market landscape.

Medical - Devices

Healthcare

CLVSF有哪些增长机遇？

Expansion into Emerging Markets: CellaVision has the opportunity to expand its presence in emerging markets, such as Asia Pacific and Latin America, where healthcare infrastructure is rapidly developing and the demand for advanced diagnostic solutions is increasing. These markets offer significant growth potential due to their large populations and unmet medical needs. Successful penetration into these regions could substantially increase CellaVision's revenue and market share over the next 3-5 years.
Product Portfolio Diversification: CellaVision can diversify its product portfolio by developing new applications and solutions for different areas of hematology and diagnostics. This could include expanding into molecular diagnostics or developing specialized solutions for specific diseases. By broadening its product offerings, CellaVision can attract new customers and increase its revenue per customer, driving long-term growth.
Strategic Partnerships and Acquisitions: CellaVision can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. Collaborating with other companies in the medical devices or diagnostics industry can provide access to new technologies, markets, and customers. Acquisitions can also be used to consolidate the market and eliminate competition, creating a stronger and more dominant player.
Increased Adoption in Veterinary Medicine: CellaVision's VET solution offers a significant growth opportunity in the veterinary medicine market. As pet ownership continues to rise and veterinary practices become more sophisticated, the demand for advanced diagnostic solutions in veterinary care is increasing. By focusing on this market, CellaVision can leverage its existing technology and expertise to capture a growing share of the veterinary diagnostics market.
Development of AI-Powered Diagnostic Tools: CellaVision can leverage artificial intelligence (AI) to develop new diagnostic tools that improve the accuracy and efficiency of cell morphology analysis. AI-powered solutions can automate the identification and classification of cells, reducing the workload for laboratory technicians and improving diagnostic accuracy. This can lead to increased adoption of CellaVision's solutions and a competitive advantage in the market.

Market Cap of $0.38B reflects CellaVision's current valuation in the medical devices market.
P/E Ratio of 23.09 indicates the price investors are willing to pay for each dollar of CellaVision's earnings.
Profit Margin of 20.2% demonstrates CellaVision's ability to generate profit from its revenue.
Gross Margin of 68.5% showcases the efficiency of CellaVision's production and pricing strategies.
Dividend Yield of 1.69% provides investors with a return on their investment through dividend payments.

CLVSF提供哪些产品和服务？

Develops and sells digital imaging solutions for blood and body fluid analysis.
Offers automated cell morphology analyzers for hospital and commercial laboratories.
Provides software applications for streamlining and standardizing diagnostic workflows.
Enables remote review of blood smears and body fluid preparations.
Offers solutions for both human and veterinary hematology.
Provides tools for assessing and monitoring staff competency in cell morphology.

CLVSF如何赚钱？

Sells automated cell morphology analyzers (CellaVision DM1200, DM9600, DC-1) to hospitals and commercial labs.
Generates recurring revenue through software licenses and service contracts.
Offers cloud-based software solutions for proficiency testing and education.
Provides digital solutions for medical microscopy in veterinary hematology.

Hospital laboratories
Commercial laboratories
Veterinary clinics and hospitals
Research institutions

Proprietary technology in digital cell morphology analysis.
Established customer base in hospitals and commercial laboratories.
Integrated hardware and software solutions.
Strong brand reputation for accuracy and reliability.

什么因素可能推动CLVSF股价上涨？

Ongoing: Expansion into emerging markets, driven by increasing healthcare investments in Asia Pacific and Latin America.
Ongoing: Product portfolio diversification with new applications for hematology and diagnostics.
Upcoming: Potential strategic partnerships or acquisitions to expand market reach and capabilities.
Ongoing: Increased adoption of CellaVision VET solutions in the growing veterinary medicine market.
Ongoing: Development and integration of AI-powered diagnostic tools for improved accuracy and efficiency.

CLVSF的主要风险是什么？

Potential: Increased competition from established medical device companies with greater resources.
Potential: Regulatory changes in the healthcare industry affecting product approvals and reimbursement.
Potential: Economic downturns impacting hospital budgets and capital expenditures.
Potential: Technological obsolescence requiring continuous innovation and product development.
Ongoing: Risks associated with OTC market listing, including limited liquidity and disclosure.

CLVSF的核心优势是什么？

Proprietary technology in digital cell morphology.
Strong brand reputation and established customer base.
High gross and profit margins.
Comprehensive suite of hardware and software solutions.

CLVSF的劣势是什么？

Limited geographic diversification.
Dependence on hospital and commercial laboratories.
Relatively small market capitalization.
OTC market listing may limit investor access.

CLVSF有哪些机遇？

Expansion into emerging markets.
Product portfolio diversification.
Increased adoption in veterinary medicine.
Development of AI-powered diagnostic tools.

CLVSF面临哪些威胁？

Competition from established medical device companies.
Regulatory changes in the healthcare industry.
Economic downturns affecting hospital budgets.
Technological obsolescence.

CLVSF的竞争对手是谁？

Avon Rubber P.L.C. — Offers a range of life support systems and CBRN protection solutions. — (AVNBF)
Bio-Rad Laboratories, Inc. — Provides a broad range of clinical diagnostics and life science research products. — (BJTRF)
bioMerieux SA — Offers diagnostic solutions for infectious diseases, industrial microbiology, and immunoassays. — (BOIRF)
Calzyme Laboratories, Inc. — Specializes in enzyme manufacturing and custom formulation services. — (CALZF)
Faron Pharmaceuticals Oy — Focuses on developing novel therapies for immunotherapy and organ protection. — (FDMDF)

Key Metrics

MoonshotScore: 52/100

Company Profile

CEO: Simon Ostergaard
Headquarters: Lund, SE
Employees: 228
Founded: 2013

AI Insight

AI analysis pending for CLVSF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does CellaVision AB (publ) do?

CellaVision AB (publ) develops, markets, and sells digital solutions for blood and body fluid analysis within the healthcare sector. Their core offering includes automated cell morphology analyzers, such as the DM1200 and DM9600, which capture digital images of cells from blood smears. These analyzers, coupled with specialized software applications, enable laboratories to automate, standardize, and simplify the morphological examination process, improving efficiency and accuracy in hematology diagnostics for hospitals and commercial labs globally.

What do analysts say about CLVSF stock?

AI analysis is pending for CLVSF, therefore current analyst ratings and price targets are unavailable. Investors should monitor for future updates regarding analyst coverage. Key valuation metrics to consider include the company's P/E ratio of 23.09, gross margin of 68.5%, and profit margin of 20.2%. Growth considerations include the company's expansion into emerging markets, product portfolio diversification, and potential for increased adoption in veterinary medicine. The OTC market listing and associated risks should also be carefully evaluated.

What are the main risks for CLVSF?

The main risks for CellaVision AB (publ) include competition from larger, more established medical device companies, potential regulatory changes affecting product approvals and reimbursement, and economic downturns impacting hospital budgets. Additionally, the company faces the risk of technological obsolescence, requiring continuous innovation and product development. As an OTC-listed stock, CLVSF also carries risks associated with limited liquidity, disclosure, and regulatory oversight, potentially leading to increased price volatility and information asymmetry for investors.